<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204516</url>
  </required_header>
  <id_info>
    <org_study_id>RNA-Mel-03</org_study_id>
    <nct_id>NCT00204516</nct_id>
  </id_info>
  <brief_title>Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens</brief_title>
  <official_title>Pilot Study of Intradermal Vaccination of Melanoma Patients With a Fixed Combination of mRNAs Compared to an Individualized Selection After Analysis of Antigen Expression in Tumor Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The purpose of the vaccination protocol is to induce specific immune responses against
      melanoma associated antigens by intradermal injections of mRNA coding for the corresponding
      antigen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      vaccination protocol to induce clinically specific immune responses against melanoma
      associated antigens by intradermal injections of mRNA coding for the corresponding antigens.
      Half of patients is treated with mRNA coding for Melan-A, Mage-A1, Mage-A3, Survivin, GP100
      and Tyrosinase. The other half of patients is treated with an individualized selection of
      mRNAs after analysis of overexpressed melanoma antigens in autologous tumor tissue. GM-CSF is
      used as an adjuvants. Phase I/II clinical trial to analyse safety and immune responses in
      stage III/IV melanoma patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>every 4 weeks</time_frame>
    <description>Side effects will be monitored using CTCAE criteria. Tolerability and toxicity profiles will be calculated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>mRNA Vacc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA coding for melanoma associated antigens</intervention_name>
    <description>mRNA vaccine s.c. applied weekly</description>
    <arm_group_label>mRNA Vacc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>Given s.c. as adjuvant drug one day after vaccine</description>
    <arm_group_label>mRNA Vacc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  malignant melanoma stage III/IV

          -  fresh frozen tumor tissue available

          -  informed consent given

          -  Karnofsky &gt;= 70%

        Exclusion Criteria:

          -  brain metastasis

          -  parallel chemotherapy

          -  systemic treatment with glucocorticoids

          -  other malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Garbe, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tuebingen, Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Thomas Eigentler</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <keyword>vaccination</keyword>
  <keyword>mRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

